British medtech firm Smith+Nephew has announced the launch of its REGENETEN Bioinductive Implant in India. With more than 100,000 procedures completed globally since its introduction, the REGENETEN implant has had a transformative impact on the way surgeons approach rotator cuff procedures.

The collagen-based REGENETEN Bioinductive Implant supports the body's natural healing response to facilitate the growth of new tendon-like tissue to biologically augment the existing tendon and change the course of disease progression.

Delivered arthroscopically through a small incision over the location of the rotator cuff tendon injury, the implant is about the size of a postage stamp and by 6 months, the implant is no longer visible, with new tendon-like tissue and oriented collagen suggestive of functional loading.

The REGENETEN Bioinductive Implant arrives in India with more than 10 years of clinically demonstrated results in 18 studies covering the entire spectrum of rotator cuff disease, from partial thickness tears to large (3-5cm) and massive (5cm+) full-thickness tears.

The prevalence of rotator cuff disease (a common cause of shoulder pain) in India was estimated to be 150,000 in 2022 with approximately 28,000 patients undergoing rotator cuff repair procedures. The total rotator cuff repair market in India is expected to reach 33,000 cases in 2023 and 39,000 in 2024, with year-over-year growth of 15%.